The IMID Forum

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor van Mulligen, from the Department of Rheumatology, Leiden University Medical Centre, as they discuss her recent paper ‘Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibodynegative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Finckh et al. and Charles‑Schoeman et al, in which authors the impact of shared epitope positivity on bDMARD effectiveness and compare treatment persistence and switching to UPA versus other advanced therapies after TNFi failure.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in PsA. This month’s conversation explores recent advances in PsA and immune-mediated inflammatory disease therapies.

Join Professor Peter Nash from the Griffith University in Brisbane; Professor Axel Finckh, from the Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland; and Bente Glintborg, an Associate Professor from the Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark as they discuss his recent paper ‘Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis’.

Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Murat Torgutalp, from the Charité – Universitätsmedizin in Berlin, as they discuss his recent paper ‘Frequency and characteristics of axial involvement in psoriatic arthritis: Results from the International Multicentre AXIS Study’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two recent studies by Etani et al. and George et al. that examine the infectious complications associated with immunosuppressive therapy in rheumatoid arthritis, including herpes zoster risk across five JAK inhibitors and the relationship between RA treatments and nonserious infections.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Chung-Mao Kao from Taichung Veterans General Hospital, as they discuss the recent publication ‘Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study’.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA.

Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Mysler et al. and Taylor et al, in which authors explore how different treatment strategies may improve outcomes in patients with RA.

Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.